CD166 demonstrated a mean 3-fold increase in response to radiation in the proteomic datasets, but was also of interest as it has previously been investigated as a vascular target in prostate cancer and an internalizing, single-chain variable fragment (scFV) antibody to CD166 developed [19]. This evidence concerns the gene ALCAM and Familial prostate cancer.